Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome

Information on the use of hypomethylating agents (HMAs) as a pre-transplant cytoreductive therapy in MDS is limited. We retrospectively evaluated outcomes of 172 adult MDS patients, who underwent allogeneic hematopoietic stem cell transplantation between January 2000 and December 2016. Patients were...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Autores principales: Modi, Dipenkumar, Kim, Seongho, Singh, Vijendra, Ayash, Lois, Alavi, Asif, Ratanatharathorn, Voravit, Uberti, Joseph P., Deol, Abhinav
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865062/
https://ncbi.nlm.nih.gov/pubmed/31010370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1605070
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares